Advanced in ABO Incompatibility

Guillermo F. Sanz

Fernando Abril Martorell Avenue, 106, 
Valencia, VC, ES 
Advanced in ABO Incompatibility
Fernando Abril Martorell Avenue, 106, 
Valencia, VC, ES 
OverviewLocationsClinical Research

Overview

Guillermo Sanz practices in Valencia, Spain. Mr. Sanz is rated as an Advanced expert by MediFind in the treatment of ABO Incompatibility. His top areas of expertise are Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), Leukemia, Acute Myeloid Leukemia (AML), and Bone Marrow Transplant.

His clinical research consists of co-authoring 212 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 5 articles in the study of ABO Incompatibility.

Gender
Male

Locations

Fernando Abril Martorell Avenue, 106, Valencia, VC 46026, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, UCB-derived, Stem and Progenitor Cells, vs. Unmanipulated UCB for Patients With Hematological Malignancies
A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, UCB-derived, Stem and Progenitor Cells, vs. Unmanipulated UCB for Patients With Hematological Malignancies
Enrollment Status: Completed
Publish Date: April 06, 2025
Intervention Type: Drug, Other
Study Drug: Omidubicel
Study Phase: Phase 3
Long Term Follow Up for Patients Who Have Received Allogeneic Stem Cell Transplantation of NiCord®/CordIn™, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells
Long Term Follow Up for Patients Who Have Received Allogeneic Stem Cell Transplantation of NiCord®/CordIn™, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells
Enrollment Status: Completed
Publish Date: October 23, 2024
Intervention Type: Genetic
Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells, in Adolescent and Adult Patients With Hematological Malignancies
Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells, in Adolescent and Adult Patients With Hematological Malignancies
Enrollment Status: Completed
Publish Date: October 22, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 2 Less Clinical Trials

212 Total Publications

Phase 1 first-in-human dose-expansion study of the oral SF3B1 modulator H3B‑8800 in lower-risk myelodysplastic syndrome.
Phase 1 first-in-human dose-expansion study of the oral SF3B1 modulator H3B‑8800 in lower-risk myelodysplastic syndrome.
Journal: Leukemia research
Published: January 21, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Sanz's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 14 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile